Sensitization of tumor necrosis factor α-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte- activating polypeptide II using recombinant vaccinia virus

Cancer Research

Volumn 59, Issue 18, 1999, Pages 4668-4674

  Gnant, Michael F X ^a,b   Berger, Adam C ^a   Huang, James ^a   Puhlmann, Markus ^a,c   Wu, Peter C ^a   Merino, Maria J ^a   Bartlett, David L ^a   Alexander Jr , H Richard ^a   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; POLYPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CANCER REGRESSION; CANCER SIZE; CELL SPECIFICITY; CONTROLLED STUDY; DNA TRANSFECTION; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; REPORTER GENE; SENSITIZATION; VACCINIA VIRUS;

ANIMALS; CELL LINE; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOKINES; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; FEMALE; GENE THERAPY; GENES, REPORTER; GROWTH INHIBITORS; HUMANS; LUCIFERASES; MELANOMA; MICE; MICE, NUDE; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; SKIN NEOPLASMS; THROMBOPLASTIN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS;

EID: 0033567895     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 72: 3666-3670, 1975.
2. Fiers, W. Tumor necrosis factor: characterization at the molecular, cellular, and in vivo level. FEBS Lett., 285: 199-212, 1992.
3. Prober, J. S. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. In: G. Bock and J. Marsh (eds.), Tumour Necrosis Factor and Related Cytotoxins, pp. 170-185. Chichester, United Kingdom: Wiley, 1984.
4. Clause, M., Ryan, J., and Stern, D. Modulation of endothetial cell haemostasis properties by TNF: insights into the role of endothelium in the host response to inflammatory stimuli. In: D. Beutler (ed.), Tumour Necrosis Factors, The molecules and their emerging role in medicine, pp. 49-64. New York: Raven Press, 1992.
5. Corti, A., and Marcucci, F. Tumour necrosis factor: strategies for improving the therapeutic index. J. Drug Target, 5: 403-413, 1998.
6. Hill, A. D., Redmond, H. P., Croke, D. T., Grace, P. A., and Bouchier-Hayes, D. Cytokine in tumour therapy. Br. J. Surg., 79: 990-997, 1992.
7. Creaven, P. J., Brenner, D. E., Cowers, J. W., Huben, R. P., Wolf, R. M., Takita, H., Arbuck, S. G., Razack, M. S., and Proefrock, A. D. A Phase I clinical trial of recombinant human tumor necrosis factor given daily for 5 days. Cancer Chemother. Pharmacol., 23: 186-191, 1989.
8. Budd, G. T., Green, S., Baker, L. H., Hersh, E. P., Weick, J. K., and Osborne, C. K. A Southwest oncology group Phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer (Phila.), 68: 1694-1695, 1991.
9. Orita, K., Fuchimoto, S., Murimoto, M., Ando, S., and Minowada, J. Early Phase II study of Interferon-γ and tumor necrosis factor-α combination in patients with advanced cancer. Acta Med. Okayama, 46: 103-112, 1992.
10. Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., III, Zentella, A., Albert, J. D., Shires, G. T., and Cerami, A. Shock and tissue injury induced by recombinant human cachectin. Science (Washington DC), 234: 470-474, 1986.
11. Eggimann, P. C. R., Chassot, P-G., Liénard, D., Gerain, J., and Lejeune, F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest, 107: 1074-1082, 1995.
12. Ksontini, R., MacKay, S. L., and Moldawer, L. L. Revisiting the role of tumor necrosis factor a and the response to surgical injury and inflammation. Arch. Surg., 133: 558-567, 1998.
13. Fraker, D. L., Alexander, H. R., and Pass, H. I. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: V. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 329-345. Philadelphia: J. B. Lippincott, 1995.
14. Alexander, H. R., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., and Rosenberg, S. A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol., 16: 1479-1489, 1998.
15. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and Interferon-γ. results of a TNF dose escalation study. J. Clin. Oncol., 14: 479-489, 1996.
16. Alexander, H. R., Bartlett, D. L., Fraker, D. L., and Libutti, S. K. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 1-19. Philadelphia: J. B. Lippincott, 1996.
17. Bartlett, D. L., Ma, G., Alexander, H. R., Libutti, S. K., and Fraker, D. L. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer (Phila.), 80: 2084-2090, 1997.
18. Eggermont, A. M., Schraffordt, K. H., Klausner, J. M., Schlag, P. M., Kroon, B. B., Ben-Air, G., and Lejeune, F. J. Isolated limb perfusion with high-dose tumor necrosis factor-α for locally advanced extremity soft tissue sarcomas. Cancer Treat. Res., 91: 189-203, 1997.
19. Lejeune, F. J., Liénard, D., Leyvraz, S., and Mirimanoff, R. O. Regional therapy of melanoma. Eur. J. Cancer, 294: 606-612, 1993.
20. Eggermont, A. M., Schraffordt, K. H., Klausner, J. M., Liénard, D., Kroon, B. B., Schlag, P. M., Ben-Air, G., and Lejeune, F. J. Isolation limb perfusion with tumor necrosis factor α and chemotherapy for advanced extremity soft tissue sarcomas. Semin. Oncol., 24: 547-555, 1997.
21. Alexander, H. R., Bartlett, D. L., and Libutti, S. K. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J. Sci. Am., 4: 2-11, 1998.
22. Nawroth, P., Handley, D., Matsueda, G., de Waal, R., Gerlach, H., Blohm, D., and Stern, D. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med., 168: 637-647, 1988.
23. Olieman, A. F. T., van Ginkel, R. J., Hoekstra, H. J., Mooyaart, E. L., Molenaar, W. M., and Koops, H. S. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann. Surg. Oncol., 4: 64-69, 1997.
24. Rosenberg, S. A. Gene therapy for cancer. J. Am. Med. Assoc., 268: 2416-2419, 1992.
25. Rosenberg, S. A., Anderson, W. F., Blaese, M., Hwu, P., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., Parkinson, D. N., and White, D. E. The development of gene therapy for the treatment of cancer. Ann. Surg., 218: 455-464, 1993.
26. Nishihara, K., Barth, R. F., Wilkie, N., Lang, J. C., Oda, Y., Kikuchi, H., Everson, M. P., and Lotze, M. T. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-γ, IL-4, IL-6, or TNF-α. Cancer Gene Ther., 2: 113-124, 1995.
27. Hu, S. X., Ji, W., Zhou, Y., Logothetis, C., and Xu, H. J. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor α gene expression. Cancer Res., 57: 3339-3343, 1997.
28. Stabe, M-J., Mauceri, H. J., Kufe, D. W., Hallahan, D. E., and Weichselbaum, R. R. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther., 4: 293-300, 1998.
29. Fushimi, K., Torigoe, K., Yamauchi, H., Furusako, S., Kurimoto, M., and Namba, M. Establishment of a human fibroblast cell line producing tumor necrosis factor (KMST-6/TNF) and growth inhibitory effects of its conditioned medium on malignant cells in culture. In Vitro Cell Dev. Biol. Anim., 34: 463-467, 1998.
30. Oppenheim, J., and Fujiwara, H. The role of cytokines in cancer. Cytokine Growth Factor Rev., 7: 279-288, 1996.
31. O'Rourke, M. G., Schmidt, C. W., O'Rourke, T. R., and Ellem, K. A. Immunotherapy, including gene therapy, for metastatic melanoma. Aust. N. Z. J. Surg., 67: 834-841, 1997.
32. Marr, R. A., Hitt, M., Muller, W. J., Gauldie, J., and Graham, F. L. Tumour therapy in mice using adenovirus vectors expression human TNF. Int. J. Oncol., 12: 509-515, 1998.
33. Bierhaus, A., Zhang, Y., Deng, Y., Mackman, N., Quehenberger, P., Haase, M., Luther, T., Muller, M., Bohrer, H., Greten, J., Martin, E., Baeverle, P. A., Wuldherr, R., Kisiel, W., Ziegler, R., Stern, D. M., and Nawroth, P. P. Mechanism of the tumor necrosis factor α-mediated induction of endothelial tissue factor. J. Biol. Chem., 270: 26419-26432, 1995.
34. Kao, J., Ryan, J., Brett, G., Chen, J., Shen, H., Fan, Y-G., Godman, G., Familletti, P., Wang, F., Pan, Y-C., Stern, D., and Clauss, M. Endothelial monocyte-activating polypeptide II: a novel tumor-derived polypeptide that activates host-response mechanisms. J. Biol. Chem., 267: 20239-20247, 1992.
35. Wu, P. C., Alexander, H. R., Huang, J., Hwu, P., Gnant, M., Berger, A. C., Turner, E., Wilson, O., and Libutti, S. K. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF) is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res., 59: 205-212, 1998.
36. Tas, M., Houghton, J., Jakobsen, A., Tomachova, T., Carmichael, J., and Murray, J. Cloning and expression of human endothelial-monocyte-activating polypeptide 2 (EMAP-2) and identification of its putative precursor. Cytokine, 9: 535-539, 1997.
37. Marvin, M., Libutti, S., Kayton, M., Kao, J., Hayward, J., Grikscheit, T., Fan, Y., Brett, J., Weinberg, A., Nowygrod, R., LoGerfo, P., Feind, C., Hansen, K., Schwartz, M., Stern, D., and Chabot, J. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J. Surg. Res., 63: 248-255, 1996.
38. Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L., and Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (Lond.), 317: 813-815, 1985.
39. Puhlmann, M., Brown, C. K., Gnant, M., Huang, J., Libutti, S. K., Alexander, H. R., and Bartlett, D. L. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther., in press, 1999.
40. Davison, A. J., and Moss, B. Structure of vaccinia virus early promoters. J. Mol. Biol., 210: 749-769, 1989.
41. Davison, A. J., and Moss, B. Structure of vaccinia virus late promoters. J. Mol. Biol., 210: 771-784, 1989.
42. Earl, P. L., and Moss, B. Expression of proteins in mammalian cells using vaccinia viral vectors. In: F. M. Ausubel, R. Kinston, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (eds.), Current Protocols in Molecular Biology, pp. 16.15.1-16.18.10. New York: Greene/Wiley Interscience, 1991.
43. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin. An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
44. Balkwill, F. R. Tumour necrosis factor. Br. Med. Bull., 45: 389-400, 1989.
45. Fiers, W. Biologic therapy with TNF: preclinical studies. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp. 295-327. Philadelphia: J. B. Lippincott, 1995.
46. Anonymous. The TNF-TIL Human Gene Therapy Clinical Protocol. Hum. Gene Ther., 1: 441-480, 1990.
47. Peplinski, G. R., Tsung, K., Whitman, E. D., Meko, J. B., and Norton, J. A. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β. Ann. Surg. Oncol., 2: 151-159, 1995.
48. Singhal, S., and Kaiser, L. R. Cancer chemotherapy using suicide genes. Surg. Oncol. Clin. N. Am., 7: 505-536, 1998.
49. Bronte, V., Carroll, M. W., Goletz, T. J., Wang, M., Overwijk, W. W., Marincola, F., Rosenberg, S. A., Moss, B., and Restifo, N. P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA, 94: 3183-3188, 1997.
50. Hodge, J. W., Abrams, S., Schlom, K. J., and Kantor, J. A. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res., 54: 5552-5555, 1994.
51. Peplinski, G. R., Tsung, K., Casey, M. J., Meko, J. B., Fredrickson, T. N., Buller, R. M. L., and Norton, J. A. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleutin-1β. Cancer J., 2: 21-27, 1996.
52. Meko, J. B., Yim, J. H., Tsung, K., and Norton, J. A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res., 55: 4765-4770, 1995.
53. Qin, H., and Chatterjee, S. K. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum. Gene Ther., 7: 1860, 1996.
54. Peplinski, G. R., Tsung, K., Meko, J. B., and Norton, J. A. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin1β. Surgery (St. Louis), 118: 185-191, 1995.
55. Peplinski, G. R., Tsung, K., and Norton, J. A. Vaccinia virus for human gene therapy. Surg. Oncol. Clin. N. Am., 7: 575-588, 1998.
56. Kim, C. J., Cormier, J., Roden, M., Gritz, L., Mazzara, G. P., Fetsch, P., Hijazi, Y., Lee, K. H., Rosenberg, S. A., and Marincola, F. M. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann. Surg. Oncol., 5: 64-76, 1998.
57. Moss, B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA, 93: 11341-11348, 1996.
58. Paoletti, E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA, 93: 11349-11353, 1996.
59. Whitman, E. D., Tsung, K., Paxson, J., and Norton, J. A. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery (St. Louis), 116: 183-188, 1994.
60. Fenner, F., Henderson, D. A., Aritz, I., Jezek, Z., and Ladnyi, I. D. Smallpox and Its Eradication. Geneva: WHO, 1988.
61. McAneny, D., Ryan, C. A., Beazley, R. M., and Kaufman, H. L. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol., 3: 495-500, 1996.
62. Cooney, E. L., Collier, A. C., Greenberg, P. D., Coombs, R. W., Zarling, J., Arditti, D. E., Hoffman, M. C., Hu, S. L., and Corey, L. Safety of an immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337: 567-572, 1991.
63. Schabel, F. M., Jr. Concepts for systemic treatment of micrometastases. Cancer (Phila.), 35: 15-24, 1975.
64. Sato, T., Yamauchi, N., Sasaki, H., Takahashi, M., Okamoto, T., Sakamaki, S., Watanabe, N., and Niitsu, Y. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res., 58: 1677-1683, 1998.
65. Clauss, M., Murray, J. C., Vianna, M., de Waal, R., Thurston, G., Nawroth, P., Gerlach, H., Gerlach, M., Bach, R., Familletti, P. C., and Stern, D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J. Biol. Chem., 265: 7078-7083, 1990.
66. Schluesener, H., Seid, K., Zhao, Y., and Meyermann, R. Localization of endothelial-monocyte-activating polypeptide II (EMAP), a novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: expression by monocytes and activated microglial cells. Glia, 20: 365-372, 1997.
67. Knies, U. E., Behrensdorf, H. A., Mitchell, C. A., Deutsch, U., Risau, W., Drexler, H. C. A., and Clauss, M. Regulation of endothelial monocyte-activating polypeptide II release by apoptosis. Proc. Natl. Acad. Sci. USA, 95: 12322-12327, 1998.
68. Libutti, S., Vargas, H., Wu, P., Turner, E., Bartlett, D., Eliot, H., Brown, C., Wong, G., Stern, D., Fraker, D., and Alexander, H. R. Endothelial monocyte activating polypeptide II (EMAP II) induces expression of tumor necrosis factor (TNF) receptor P55 (R1) by endothelial cells. Proc. Soc. Surg. Oncol., 70: 24, 1997.
69. Wu, P. C., Berger, A. C., Huang, J., Gnant, M., Turner, E., Alexander, H. R., and Libutti, S. K. In vivo tumors that overexpress endothelial monocyte-activating polypeptide II demonstrate upregulation of tumor necrosis factor receptor p55 on tumor neovasculature. Surg. Forum, 49: 436-438, 1998.